ArticleMolecular biology reports2026
Neupogen/MSCs conditioned media inhibit HEp-2 laryngeal cancer cells proliferation by down regulating miRNA 21expression and ROS production.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe process of cancer progression is maintained through a feedback loop whereby reactive oxygen species (ROS) induce inflammatory cytokines, which activate STAT3 and result in miRNA-21 upregulation. miRNA-21 enhances the AKT signaling pathway and suppresses PTEN, promoting the proliferation of the cancerous cells and the additional production of ROS. Neupogen exerts both anti-inflammatory oxidant effects, our previous study revealed the anticancer effect of neupogean on colorectal adenocarcinoma cells, thus we aimed to investigate the possible modulating role of Neupogen on tumor microenvironment by breaking the inflammatory cytokine-STAT3-miRNA21 loop.
methodsHep2 cells were cultured in four conditions (1) untreated Hep2 cells, (2) Hep2 cells treated with Neupogen, (3) Hep2 cells treated with MSCs-conditioned media, and (4) Hep2 cells treated with both MSCs-conditioned media and Neupogen. MTT assay was used to assess cell proliferation, ROS levels was assessed by ELISA, STAT3 protein expression was assessed by western blotting technique, and qRT-PCR was used to assess the gene expression of IL-6, TNF-alpha, VEGF, and miRNA-21.
resultsNeupogen or MSCs-conditioned media treatment significantly decreased the ROS accumulation, STAT3 expression, pro-inflammatory cytokines, miRNA-21 levels, and cell proliferation. The combination treatment generated the highest inhibitory effects in all measured parameters.
conclusionNeupogen and MSCs-conditioned media are effective in suppressing the proliferation of Hep2 cells by targeting various components of the ROS-cytokine- STAT3-miRNA-21 signaling axis. Their combined therapy has shown potent anticancer effects, which are promising to be used in multi-targeted cancer treatment.
Indexed as
Identifiers
42340484What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.